From trial phases to personalized care, here’s how healthcare providers can navigate cancer clinical trials and guide ...

ATH-1105 is the Company's novel, orally available, brain-penetrant, next-generation small molecule drug candidate designed to ...

HER-096 is a first-in-class agent in development for the treatment of Parkinson’s disease with disease modifying potential and convenient subcutaneous administration Successful completion of the first ...

Rejuvenate Biomed, an AI-enabled, clinical-stage biotech company developing safe, synergistic combination therapeutics that alter the course of age-related diseases, announced today that the first ...

SYL1801 is an investigational siRNA therapy administered via eye drops, rather than intravitreal injection, to treat nAMD.

New Delhi: Rejecting the proposal for the local Phase III clinical trial waiver, the Subject Expert Committee (SEC) ...

We look forward to supporting innovation in the life science industry by continuing to deliver effective risk transfer ...

researchers and participants throughout all phases of clinical research and is tailored to meet the regulatory requirements of more than 100 territories, ensuring smooth and compliant trial ...

Phase 1 results of a next-generation treatment targeting KRAS G12C, the cause of lung cancer, colon cancer, and pancreatic ...

SAN ANTONIO, May 1, 2025 /PRNewswire/ -- Summit Clinical Research, LLC ("Summit"), a leading ... of key senior leaders to drive the next phase of Summit's growth. Dr. Naim Alkhouri, MD, FAASLD ...

Herantis Pharma Plc - Press release First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson's disease HER-096 is a first-in-class agent in development for ...

The first phase of construction is beginning on a new $2.19 billion health care, training and research facility for UNMC and Nebraska Medicine.